Study guide

12.1 Common Dermatoses & Dermatological Emergencies

Professional and Linguistic Assessments Board Part 1 PLAB 1

Track your progress as you read

Finished sections get a check mark.

1 Introduction

About the PLAB 1 Exam

2 Chapter 1: Acute Medicine, Resuscitation & Clinical Emergencies

1.1 The ABCDE Approach, Adult Resuscitation & Shock 1.2 Sepsis, Sepsis Six Protocol & Septic Shock 1.3 Anaphylaxis & Acute Airway Emergencies 1.4 Clinical Toxicology & Acute Poisoning 1.5 Major Trauma, Head Injury, Burns & Environmental Emergencies

3 Chapter 2: Cardiovascular Medicine & Vascular Disorders

2.1 Acute Coronary Syndromes (STEMI & NSTEMI/Unstable Angina) 2.2 Heart Failure & Cardiogenic Shock 2.3 Cardiac Arrhythmias & Syncope 2.4 Hypertension, Valvular Heart Disease & Aortic Emergencies 2.5 Infective Endocarditis, Pericardial Disease, Myocarditis & Cardiomyopathies 2.6 Peripheral Arterial Disease, Aortic Aneurysm & Venous Disease

4 Chapter 3: Respiratory Medicine

3.1 Asthma: Diagnostic Criteria, Chronic Stepping & Acute Exacerbations 3.2 COPD: Staging, Long-Term Management & Acute Exacerbations 3.3 Pneumonia & Lower Respiratory Tract Infections 3.4 Venous Thromboembolism, Pleural Disease & Pneumothorax 3.5 Lung Cancer, Interstitial & Suppurative Lung Disease, Sleep Apnoea & Respiratory Failure

5 Chapter 4: Gastroenterology, Hepatobiliary & General Surgery

4.1 Upper Gastrointestinal Bleeding & Dyspepsia 4.2 Lower Gastrointestinal Bleeding, IBD & Colorectal Malignancy 4.3 Acute Abdomen, Bowel Obstruction & Perforation 4.4 Hepatobiliary Disease, Cirrhosis & Acute Pancreatitis 4.5 Functional, Malabsorptive & Infective Bowel Disorders, Anorectal Disease, Hernias & MASLD

6 Chapter 5: Renal Medicine, Urology & Fluid/Electrolyte Balance

5.1 Acute Kidney Injury & KDIGO Staging 5.2 Chronic Kidney Disease & Glomerular Disorders 5.3 Electrolyte Emergencies: Potassium, Sodium & Calcium 5.4 Urology: Urinary Tract Infections, Renal Colic & Urinary Retention 5.5 Urological Cancers, Prostate Disease & Scrotal Emergencies

7 Chapter 6: Endocrinology & Metabolic Medicine

6.1 Diabetes Mellitus: Diagnostic Criteria & Chronic Management 6.2 Diabetic Emergencies: DKA & Hyperosmolar Hyperglycaemic State 6.3 Thyroid Disorders: Hypothyroidism, Thyrotoxicosis & Thyroid Storm 6.4 Adrenal & Pituitary Disorders: Addisonian Crisis & Pituitary Disease

8 Chapter 7: Neurology & Neurosciences

7.1 Acute Stroke, TIA & Intracranial Haemorrhage 7.2 Acute & Chronic Headaches, Giant Cell Arteritis & CNS Infections 7.3 Seizures, Status Epilepticus & Epilepsy Management 7.4 Neuromuscular Disorders & Movement Disorders 7.5 Raised Intracranial Pressure, Brain Tumours, Cranial Nerve Lesions & Spinal Cord Disorders

9 Chapter 8: Psychiatry & Mental Health

8.1 Affective Disorders: Depression, Bipolar Disorder & Suicide Risk Assessment 8.2 Psychosis, Schizophrenia & Acute Agitation 8.3 Cognitive Disorders, Substance Misuse & the Mental Health Act 8.4 Anxiety Disorders, OCD, PTSD, Eating Disorders, Personality Disorders & Somatic Presentations 8.5 Perinatal, Child & Adolescent and Neurodevelopmental Mental Health

10 Chapter 9: Obstetrics, Gynaecology & Sexual Health

9.1 Early Pregnancy: Miscarriage & Ectopic Pregnancy 9.2 Antenatal & Peripartum Emergencies: Pre-Eclampsia & Haemorrhage 9.3 Common Gynaecological Presentations & Gynaecological Oncology 9.4 Contraception, Emergency Contraception & Sexually Transmitted Infections 9.5 Routine Antenatal Care, Labour & Obstetric Emergencies 9.6 Menopause & HRT, Subfertility, Prolapse & Urinary Incontinence

11 Chapter 10: Paediatrics & Child Health

10.1 The Febrile Child, Sepsis & Meningococcal Disease 10.2 Paediatric Respiratory Distress: Croup, Bronchiolitis & Wheeze 10.3 Paediatric Abdominal Emergencies, Dehydration & Neonatal Jaundice 10.4 Child Safeguarding, Non-Accidental Injury & Developmental Milestones 10.5 Neonatology & Congenital Heart Disease 10.6 Paediatric Orthopaedics, Growth, Childhood Cancer & Common Chronic Problems

12 Chapter 11: Musculoskeletal Medicine & Rheumatology

11.1 Inflammatory Arthropathies & Connective Tissue Diseases 11.2 Crystal Arthropathies (Gout & Pseudogout) & Septic Arthritis 11.3 Osteoporosis, Common Fractures & Orthopaedic Emergencies 11.4 Osteoarthritis, Low Back Pain, Polymyalgia Rheumatica, Fibromyalgia & Soft Tissue Disorders

13 Chapter 12: Dermatology, ENT & Ophthalmology

12.1 Common Dermatoses & Dermatological Emergencies 12.2 ENT Presentations: Infections, Epistaxis, Vertigo, Hearing Loss & Head and Neck Lumps 12.3 The Acute Red Eye: Glaucoma, Uveitis & Keratitis 12.4 Sudden & Gradual Vision Loss, Retinal Disorders & the Visual Pathway 12.5 Skin Infections, Infestations, Childhood Rashes & Skin Cancer

14 Chapter 13: Haematology, Oncology & Palliative Care

13.1 Anaemias & Blood Transfusion Medicine 13.2 Haematological Malignancies: Leukaemias, Lymphomas & Myeloma 13.3 Haemostasis, Coagulation Disorders & Anticoagulant Reversal 13.4 Oncological Emergencies & Palliative Symptom Management 13.5 Breast Disease, Cancer Screening & Suspected Cancer Referral

15 Chapter 14: Perioperative Care, Safe Prescribing & Clinical Pharmacology

14.1 Preoperative Assessment & Perioperative Medication Management 14.2 Postoperative Complications & Fluid Therapy 14.3 High-Risk Medications & Therapeutic Drug Monitoring 14.4 Safe Prescribing Principles & Antimicrobial Stewardship

16 Chapter 15: Medical Ethics, Law & UK Clinical Practice

15.1 GMC Good Medical Practice, Professionalism, Teamwork & Quality Improvement 15.2 Consent, Capacity & the Mental Capacity Act 2005 15.3 Confidentiality, Statutory Reporting & DVLA Regulations 15.4 End-of-Life Decisions, DNACPR, Organ Donation, Adult Safeguarding & Domestic Abuse

17 Chapter 16: Infectious Diseases, Travel Medicine & Infection Prevention

16.1 Tuberculosis, HIV, Hepatitis B & C and Needlestick Injuries 16.2 Fever in the Returning Traveller, Zoonoses, Notifiable Diseases & Infection Prevention

18 Chapter 17: Older Adults, Population Health, Genetics & Clinical Imaging

17.1 Frailty, Falls, Polypharmacy, Continence & Pressure Ulcers 17.2 Medical Statistics, Diagnostic Tests & Critical Appraisal 17.3 Public Health, Screening Principles, Health Inequalities & Health Promotion 17.4 Genetics, Genomics & Pharmacogenomics 17.5 Clinical Imaging: Choosing Tests, Radiation Safety & Interpreting X-rays

12.1 Common Dermatoses & Dermatological Emergencies

Key Takeaways Explain This Topic AI

Atopic eczema maintenance relies on liberal emollients and stepped topical corticosteroids matched to anatomical site; potent steroids must never be applied to the face or flexures to prevent irreversible skin atrophy and telangiectasia.

Chronic plaque psoriasis is treated first-line with a once-daily combination of a potent topical corticosteroid and a vitamin D analogue (calcipotriol) for up to 4 weeks, with phototherapy and systemic agents reserved for extensive or refractory disease.

Acne vulgaris stepped management pairs topical retinoids with benzoyl peroxide, adding a maximum 12-week course of oral lymecycline or doxycycline for inflammatory disease; severe nodulocystic acne warrants consultant-initiated oral isotretinoin under strict pregnancy prevention protocols.

Dermatological emergencies demand rapid clinical triage: immediate systemic aciclovir for eczema herpeticum, urgent burn centre transfer and drug withdrawal for SJS/TEN based on BSA detachment and SCORTEN, emergency surgical debridement with IV clindamycin for necrotising fasciitis, and suspected cancer pathway referral with excision biopsy for suspected melanoma.

Last updated: October 2026

Common Dermatoses & Dermatological Emergencies

Dermatological presentations in acute clinical practice range from chronic, relapsing inflammatory disorders requiring stepped outpatient therapy to life-threatening dermatological emergencies requiring immediate resuscitation, high-dependency organ support, and surgical debridement.

  • Common Chronic Dermatoses
  • Atopic Eczema (Atopic Dermatitis)

Atopic eczema is a chronic, relapsing, highly pruritic inflammatory skin disorder resulting from a complex interplay between epidermal barrier disruption (characterised by loss-of-function mutations in the filaggrin gene [ FLG ]), environmental allergens, and immune dysregulation with predominantly Th2-skewed cytokine responses.

Clinical Presentation: Intense pruritus is the hallmark symptom ("the itch that rashes"). Lesions appear as ill-defined, erythematous, xerotic patches and plaques accompanied by oedema, excoriations, and crusting. In chronic cases, repeated rubbing and scratching produce flexural lichenification (thickened, leathery skin with exaggerated markings). The anatomical distribution evolves characteristically with patient age:

Infants (<1 year): Typically involves the cheeks, forehead, scalp, and extensor surfaces of the limbs; the nappy/diaper area is characteristically spared due to ambient moisture.

Children & Adults: Predominantly localises to flexural creases, particularly the antecubital and popliteal fossae, anterior neck, wrists, hands, and periorbital regions.

Maintenance Emollient Therapy: Liberal, frequent application of emollients forms the cornerstone of management. Emollients should be smoothed onto the skin in the direction of hair growth rather than vigorously rubbed, applied at least 2–3 times daily even when skin appears clear, and used as soap substitutes.

Stepped Topical Corticosteroid (TCS) Ladder: During active inflammatory flares, topical corticosteroids are applied once daily in short courses (typically 7–14 days) to induce remission.

Potency Class Representative Generic Agent Proprietary Name Typical Clinical Indications & Cautions

Mild Hydrocortisone 0.5%–2.5% Daktacort (combined), Mildison Face, neck, eyelids, flexural creases, infants, mild flares

Moderate Clobetasone butyrate 0.05% Eumovate Trunk and extremities in young children; moderate flexural flares

Potent Betamethasone valerate 0.1%; Fluticasone propionate 0.05% Betnovate; Cutivate Severe flares on trunk and limbs; chronic lichenified eczema

Very Potent Clobetasol propionate 0.05% Dermovate Thickened, hyperkeratotic lesions on palms, soles; refractory plaques (max 2–4 weeks)

Warning

Steroid Application Rules & The Fingertip Unit (FTU): One FTU is defined as the amount of cream or ointment expressed from a standard 5 mm nozzle tube from the distal skin crease to the tip of an adult index finger (~0.5 g). One FTU adequately covers an anatomical area equivalent to two adult hand palms (including fingers). Potent and very potent topical corticosteroids must never be prescribed for the face, eyelids, or intertriginous/flexural areas (groin, axillae), where thin skin and high percutaneous absorption trigger rapid cutaneous atrophy, irreversible striae distensae, telangiectasia, and peri-orofacial dermatitis.

Psoriasis Vulgaris (Chronic Plaque Psoriasis)

Psoriasis is an autoimmune, polygenic dermatosis driven by abnormal crosstalk between dendritic cells, T-helper 17 (Th17) lymphocytes, and epidermal keratinocytes. Hyperstimulation by interleukin-23 (IL-23) and interleukin-17 (IL-17) shortens the epidermal cell cycle transit time from the normal 28 days to merely 3–4 days, producing prominent hyperkeratosis and parakeratosis.

Clinical Presentation: Chronic plaque psoriasis accounts for >80% of presentations, manifesting as symmetrical, well-demarcated, salmon-pink or erythematous plaques capped with thick, adherent, silvery-white micaceous scales on extensor surfaces (elbows, knees, scalp, lumbosacral spine, umbilicus).

Diagnostic Examination Signs:

Auspitz Sign: Gentle scraping or mechanical removal of silvery scales reveals pinpoint capillary bleeding points, reflecting the thinning of the suprapapillary epidermis overlying dilated, tortuous dermal papillae capillaries.

Koebner Phenomenon (Isomorphic Response): Development of characteristic psoriatic lesions at sites of cutaneous mechanical trauma, surgical incisions, or excoriations 7–14 days following injury.

Extracutaneous Manifestations: Nail changes occur in up to 50% of patients, including thimble-like nail pitting, onycholysis (separation of nail plate from bed), subungual hyperkeratosis, and pathognomonic "oil-drop" or "salmon patch" discoloration. Up to 30% develop psoriatic arthritis (dactylitis "sausage digits", enthesitis, asymmetrical oligoarthritis, or sacroiliitis).

Stepped Management (NICE Guidelines):

First-Line Topical Therapy: Apply a potent topical corticosteroid (e.g. betamethasone valerate) combined with a vitamin D analogue (e.g. calcipotriol) once daily for up to 4 weeks (available as fixed-combination gel or foam).

Second-Line Topical Therapy: If improvement is insufficient after 4 weeks, switch to a vitamin D analogue applied twice daily, or a potent topical corticosteroid applied twice daily for 2–3 weeks, or a coal tar preparation.

Specialist Secondary Care: Extensive disease (>10% BSA) or refractory plaques warrant narrowband ultraviolet B (NB-UVB) phototherapy (2–3 times weekly), followed by oral systemic agents: oral methotrexate (first-line systemic; requires folic acid co-prescription and regular monitoring of FBC, LFTs, and renal function), ciclosporin, or acitretin. Severe refractory disease qualifies for biologic therapies targeting TNF-alpha (adalimumab), IL-17 (secukinumab), or IL-23 (guselkumab).

Acne Vulgaris

Acne vulgaris is a chronic multifactorial disorder of the pilosebaceous unit involving follicular hyperkeratinisation, androgen-driven sebum hypersecretion, proliferation of Cutibacterium acnes , and host inflammatory responses.

Morphological Lesion Types: Non-inflammatory lesions include open comedones ("blackheads", oxidised melanin/lipids) and closed comedones ("whiteheads", obstructed follicles). Inflammatory lesions include erythematous papules, pustules, deep tender nodules, and pseudocysts, carrying a high risk of permanent atrophic "ice-pick" or hypertrophic scarring.

NICE Stepped Treatment Algorithm (NG198):

Step 1 (Mild-to-Moderate Acne): First-line topical fixed-combination therapy for 12 weeks: topical retinoid plus benzoyl peroxide (BPO) (e.g. adapalene 0.1% + benzoyl peroxide 2.5% gel applied once daily at night), OR topical clindamycin 1% + tretinoin 0.025%, OR topical clindamycin 1% + BPO 5%. Topical antibiotic monotherapy is strictly contraindicated to prevent widespread antimicrobial resistance.

Step 2 (Moderate-to-Severe Acne): Oral tetracycline antibiotic ( lymecycline 408 mg once daily or doxycycline 100 mg once daily ) prescribed for a maximum duration of 12 weeks , ALWAYS co-prescribed with a topical retinoid or BPO to prevent resistant bacterial selection. In females, combined oral contraceptive pills containing anti-androgenic progestogens (e.g. co-cyprindiol / Dianette) provide a viable alternative.

Step 3 (Severe Nodulocystic or Scarring Acne): Urgent referral to a consultant dermatologist for oral isotretinoin (Roaccutane).

Caution

Oral Isotretinoin Safety Mandates: Isotretinoin is a potent teratogen capable of inducing catastrophic embryopathy (craniofacial, cardiac, and CNS malformations). Initiation is legally restricted to consultant dermatologists under a mandatory Pregnancy Prevention Programme (PPP) . Females able to become pregnant must use at least one highly effective (user-independent) method, such as an implant or intrauterine device, or two complementary user-dependent methods , from 1 month before, throughout, and for 1 month after treatment, with medically supervised pregnancy testing before, during (ideally monthly) and after treatment. MHRA measures introduced in 2023 also require two independent prescribers to agree before starting isotretinoin in patients under 18 , and assessment of mental health and sexual function before and during treatment. Prescribers must obtain baseline and periodic liver function tests (LFTs) and fasting lipid panels (risk of severe hypertriglyceridaemia and pancreatitis), and actively screen for mood changes, depression, and suicidal ideation at every review.

  • Dermatological Emergencies
  • 1. Eczema Herpeticum (Kaposi's Varicelliform Eruption)

Eczema herpeticum represents a life-threatening, disseminated cutaneous infection caused by Herpes Simplex Virus (predominantly HSV-1, less commonly HSV-2) superinfecting pre-existing dermatoses with an impaired stratum corneum barrier, most frequently atopic eczema.

Clinical Presentation: The patient (often a young child with chronic atopic eczema) presents with an abrupt, acute deterioration characterised by high fever, malaise, chills, irritability, and tender regional lymphadenopathy. Examination reveals a widespread, explosive eruption of monomorphic, dome-shaped, umbilicated vesicles that rapidly rupture, coalesce, and evolve into punched-out circular erosions with overlying hemorrhagic or honey-coloured crusts. Commonest sites include the face, neck, and upper trunk.

Emergency Management:

Immediate Systemic Antiviral Therapy: Commence oral aciclovir immediately (or IV aciclovir if the patient is systemically toxic, vomiting, neonate, or immunocompromised). Clinical administration must never be delayed to await diagnostic viral PCR swabs or electron microscopy results.

Ophthalmic Assessment: If vesicles are present in the peri-orbital region or eyelids, obtain an urgent emergency ophthalmology review to examine for herpes simplex dendritic keratitis, which risks corneal ulceration and permanent visual impairment.

Supportive & Antibacterial Care: Secondary bacterial superinfection with Staphylococcus aureus or Streptococcus pyogenes is common; add IV or oral flucloxacillin. Topical corticosteroids must be withheld during the initial acute phase.

2. Stevens-Johnson Syndrome (SJS) & Toxic Epidermal Necrolysis (TEN)

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are severe, life-threatening, cell-mediated (CD8+ cytotoxic T-cell and natural killer cell-mediated release of granulysin and perforin) type IV hypersensitivity reactions that trigger widespread keratinocyte apoptosis and full-thickness epidermal necrolysis.

Culprit Etiological Triggers: >80% of cases are drug-induced, typically manifesting 1–4 weeks following the initiation of therapy. Common culprits include: allopurinol , aromatic antiepileptics ( carbamazepine , phenytoin , lamotrigine ), sulfonamides (co-trimoxazole), NSAIDs (meloxicam, piroxicam), and nevirapine .

Clinical Presentation: A prodromal influenza-like illness (high fever, malaise, cough, sore throat, stinging eyes) precedes cutaneous manifestations by 1–3 days. Skin lesions commence as tender, dusky, ill-defined erythematous macules that coalesce into atypical flat targetoid lesions (two concentric zones) spreading centrifugally from the face and trunk to the extremities.

Nikolsky's Sign: Pathognomonic and positive: gentle lateral sliding pressure applied with a finger to erythematous skin elicits epidermal shearing and sheet-like detachment of the epidermis from the underlying dermis.

Mucocutaneous Detachment Spectrum:

Classification Body Surface Area (BSA) of Epidermal Detachment Mucosal Involvement Clinical Characteristics

Stevens-Johnson Syndrome (SJS) <10% BSA Severe involvement of ≥2 mucous membranes Dusky targetoid macules, mucosal sloughing, discrete flaccid bullae

SJS / TEN Overlap 10% – 30% BSA Severe involvement of ≥2 mucous membranes Coalescent necrotic macules, advancing epidermal detachment

Toxic Epidermal Necrolysis (TEN) >30% BSA Severe involvement of ≥2 mucous membranes Extensive sheet-like scalded skin shedding leaving denuded, bleeding dermis

Mucosal Manifestations: Involve ≥2 mucosal sites in >90% of patients: hemorrhagic, crusted, painful stomatitis of the vermilion border of the lips; purulent conjunctivitis with risk of pseudomembrane formation, symblepharon (adhesion of eyelid to globe), and corneal melting; and severe erosive genital/urethral ulceration.

The SCORTEN Prognostic Score: Assessed within the first 24–48 hours of admission to calculate mortality risk (1 point per criterion: Age ≥40 years; Heart rate ≥120 bpm; Malignancy present; Initial BSA detachment >10%; Serum urea >10 mmol/L; Serum glucose >14 mmol/L; Serum bicarbonate <20 mmol/L). A score of 0–1 carries ~3% mortality, whereas a score of ≥5 predicts >90% mortality.

Emergency Resuscitation & Management:

Immediate Cessation of Culprit Drug: Stop all non-essential and suspected medications immediately; early drug withdrawal significantly reduces mortality.

Transfer to Specialized Burns Centre or Intensive Care Unit: Environmental isolation in a thermoregulated room (warmed to 30–32°C) to prevent hypothermia due to loss of cutaneous thermoregulation.

Fluid and Electrolyte Resuscitation: Denuded skin surfaces lead to massive evaporative fluid, protein, and electrolyte losses analogous to major thermal burns. Intravenous crystalloid infusion (Hartmann's solution) should be guided by urine output targets (0.5–1.0 mL/kg/h).

Protective Wound Dressings: Avoid aggressive surgical debridement; apply non-adherent silicone or petrolatum-impregnated dressings under strict sterile conditions.

Multidisciplinary Organ Protection: Emergency ophthalmology involvement (intensive preservative-free lubricants, daily release of symblepharon adhesions, topical antibiotics), urology/gynaecology consultation to prevent vaginal/urethral stenosis, and multimodal analgesia.

3. Necrotising Fasciitis

Necrotising fasciitis is a fulminant, rapidly progressive soft tissue infection tracking along the deep fascial planes, leading to microvascular thrombosis, liquefactive necrosis of subcutaneous fat and fascia, and overwhelming septic shock.

Microbiology:

Type 1 (Polymicrobial, ~70%): Synergistic mixture of obligate anaerobes ( Bacteroides , Peptostreptococcus ) and facultative aerobes ( Enterobacteriaceae , Streptococcus species); classically seen in elderly, diabetic, or immunocompromised patients following abdominal surgery, perianal sepsis, or perineal trauma ( Fournier's gangrene ).

Type 2 (Monomicrobial, ~30%): Caused by Group A Streptococcus ( Streptococcus pyogenes ) , alone or co-infecting with Staphylococcus aureus ; typically occurs in previously healthy individuals following minor cutaneous trauma, insect bites, or surgical procedures.

Clinical Presentation: The hallmark early diagnostic sign is excruciating, severe pain entirely out of proportion to the subtle overlying physical skin changes (which may show only mild erythema and soft tissue swelling). The infection spreads with alarming velocity. Late findings include dusky purple or violaceous skin discoloration, cutaneous blistering with hemorrhagic bullae, subcutaneous crepitus (gas in tissues, predominantly in Type 1), focal skin anaesthesia (caused by ischaemic thrombosis of cutaneous nerves running through the necrotic fascia), and rapid progression to septic shock (hypotension, tachycardia, refractory lactic acidosis, multiorgan failure).

Emergency Management Protocol:

Immediate Radical Surgical Debridement: Necrotising fasciitis is a surgical emergency; emergency surgical exploration and wide radical excision of all non-viable, necrotic tissue and fascia is the definitive life-saving intervention. Medical management alone carries a 100% mortality rate; delays in surgical debridement increase mortality exponentially.

Empirical Broad-Spectrum Intravenous Antimicrobials: Immediately administer high-dose IV broad-spectrum antibiotics: e.g. IV meropenem (or piperacillin-tazobactam) PLUS IV clindamycin PLUS IV vancomycin (or teicoplanin for MRSA coverage). Clindamycin is specifically included because its inhibition of bacterial ribosomal 50S protein synthesis arrests the transcription and release of streptococcal pyrogenic exotoxins and toxic shock syndrome toxin (TSST-1), blunting cytokine storm.

Hemodynamic Resuscitation: High-volume IV crystalloids, early invasive arterial monitoring, central venous access, and vasopressor support in an intensive care setting.

4. Malignant Melanoma

Malignant melanoma arises from the neoplastic transformation of melanocytes, representing the deadliest form of cutaneous malignancy due to its propensity for early lymphovascular invasion and distant metastasis. Primary risk factors include intermittent intense ultraviolet (UV) radiation exposure (particularly blistering sunburns in childhood/adolescence), fair skin (Fitzpatrick skin phototypes I and II), multiple atypical dysplastic naevi (>50), family history, and genetic mutations in CDKN2A and BRAF (V600E).

Clinical Detection: The ABCDE Diagnostic Rule:

  • Criterion Feature Clinical Warning Sign
  • A Asymmetry One half of the pigmented lesion does not mirror or match the opposite half
  • B Border Irregularity Edges are notched, scalloped, ragged, indented, or poorly defined

C Colour Variegation Non-uniform pigmentation displaying variable shades of tan, dark brown, black, with red, white, or blue foci

D Diameter Maximum diameter ≥6 mm (roughly the size of a pencil eraser; though early melanomas can be smaller)

E Evolution / Change The single most important clinical criterion: any dynamic change in lesion size, shape, surface contour, elevation, colour, or new-onset bleeding, crusting, or persistent pruritus

Histopathological Prognosis: Breslow thickness —the vertical microscopic measurement in millimetres from the top of the epidermal granular layer (or base of ulceration) to the deepest invasive malignant melanocyte in the dermis—is the single most significant independent prognostic determinant of overall survival and nodal metastasis.

Management Pathway: Any pigmented lesion suspicious for melanoma (NICE NG12: a weighted 7-point checklist score of 3 or more , or dermoscopy suggesting melanoma) needs a suspected cancer pathway referral to a specialist dermatology service. The diagnostic procedure of choice is a complete excisional biopsy with a 2 mm clinical margin and an intact cuff of subcutaneous fat. Partial biopsies (incisional, shave, or punch biopsies) are strictly contraindicated because they risk sampling error, incomplete assessment of maximum Breslow thickness, and inaccurate pathological staging. Once melanoma is histologically confirmed, formal wide local excision (WLE) with safety margins determined by Breslow thickness (1 cm margin for Breslow <1 mm; 2 cm margin for Breslow ≥2 mm) is performed, alongside consideration of sentinel lymph node biopsy (SLNB).

Loading diagram... Severe Cutaneous Adverse Reactions (SCAR) & Dermatological Emergencies Triage